About xenon pharmaceuticals inc - XENE
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
XENE At a Glance
Xenon Pharmaceuticals, Inc.
200-3650 Gilmore Way
Burnaby, British Columbia V5G 4W8
| Phone | 1-604-484-3300 | Revenue | 7.50M | |
| Industry | Pharmaceuticals: Major | Net Income | -345,910,000.00 | |
| Sector | Health Technology | Employees | 370 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
XENE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 473.62 |
| Price to Book Ratio | 6.164 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.127 |
| Enterprise Value to Sales | 401.495 |
| Total Debt to Enterprise Value | 0.003 |
XENE Efficiency
| Revenue/Employee | 20,270.27 |
| Income Per Employee | -934,891.892 |
| Receivables Turnover | 5.47 |
| Total Asset Turnover | 0.007 |
XENE Liquidity
| Current Ratio | 13.415 |
| Quick Ratio | 13.415 |
| Cash Ratio | 13.134 |
XENE Profitability
| Gross Margin | 66.093 |
| Operating Margin | -4,974.267 |
| Pretax Margin | -4,598.587 |
| Net Margin | -4,612.133 |
| Return on Assets | -33.768 |
| Return on Equity | -51.757 |
| Return on Total Capital | -58.658 |
| Return on Invested Capital | -51.219 |
XENE Capital Structure
| Total Debt to Total Equity | 1.366 |
| Total Debt to Total Capital | 1.347 |
| Total Debt to Total Assets | 0.809 |
| Long-Term Debt to Equity | 1.102 |
| Long-Term Debt to Total Capital | 1.087 |